February 28, 2021
Today is World Rare Disease Day and we would like to acknowledge the recent therapeutic advances that have brought hope to many patients and their families. Thank you to all who work in this field! Our team has a special interest in rare diseases; stemming both from the experience of two medical writers from our medical communication agency (Emma Pilling and Françoise Nourrit-Poirette) at Orphanet, and from our coverage of the North American Cystic Fibrosis Conference (NACFC). Marielle Romet, who is based in the United States, has attended the NACFC 4 years in a row and our team has coordinated the production of conference reports that were published live by the Pediatric Archives in partnership with the French Cystic Fibrosis Society, Elsevier and Vertex, and with the help of Profs. Isabelle Sermet, Isabelle Fajac, and Philippe Reix, and Drs. Valérie Urbach and Nadine Desmazes-Dufeu, and a group of French pulmonologists.
February 27, 2021
Today is World Anosmia Awareness Day. Until recently, anosmia was a term understood mainly by patients, physicians and researchers; however, this term has now become familiar to the general public because anosmia is one of the common symptoms of Covid-19, particularly of the mild form of the disease (Lechien et al. 2021). Anosmia involves not only loss of the ability to detect odors, but also loss of the ability to sense food aromas and perceive flavors; the sense of taste only allowing the detection of sweet, savory, sour, bitter and salty food. Loss of smell is very disturbing: it means loosing the everyday markers that are closely linked to odors and aromas. Although loss of smell is a short-term symptom for most Covid 19 patients, anosmia has been reported to persist for at least 6 months in patients with long Covid-19 (Lechien et al. 2021). Olfactory training is currently the only effective therapy for the treatment post-viral anosmia (French National Authority for Health, 2021), but oral corticosteroids may improve recovery of the sense of smell in Covid-19 patients (Le Bon et al. 2021; Vaira et al. 2020).
February 19, 2021
Predatory journals bias science through the publication of low-quality, non-peer-reviewed articles.
The scale of this problem has recently been highlighted in the latest news round-up from Nature: a recent analysis found that 164,000 articles published by potentially predatory journals from 2015 to 2017 were indexed in the Scopus database, accounting for almost 3% of the articles indexed during this period.
A previous analysis found that some predatory journals were also indexed in PubMed.
These criteria and tools can help you recognize predatory journals.
Every medical writer at Santé Active Édition – Synergy Pharm verifies the legitimacy of the journal they recommend to their clients, or the journal suggested by the corresponding authors, for the publication of their scientific article. This has already allowed us to avoid disappointment on several occasions!
February 11, 2021
On the International Day of Women and Girls in Science, we wish to recognize the contribution of our team of female medical and scientific writers. Each member of our medical writing team has a PhD in science and has post-doctoral research experience. For several years they have been helping our clients to showcase their results: writing, editing, and rewriting publications for peer-reviewed journals, conference summaries, posters and slideshow presentations; drafting regulatory and clinical documents (IMPDs, IBs, CSPs, CSRs, CTDs, PIPs, CERs, etc.); producing lay texts containing key medical information for patients (website content, brochures, sketchnotes, etc.); and translating scientific documents.
December 15, 2020
Sanofi renews partnership with the World Health Organization (WHO) for 5 extra years, thereby consolidating a 20-year collaboration to fight Neglected Tropical Diseases (NTDs) and eliminate sleeping sickness before 2030!
Among its recent activities, Synergy Pharm is proud of its participation in the project for the first all-oral treatment for sleeping sickness — a disease caused by the Trypanosoma brucei gambiense parasite and transmitted to humans by the tsetse fly. Fexinidazole is the result of a fruitful collaboration between the Drugs for Neglected Diseases initiative (DNDi) — an international, non-profit, independent research organization — and Sanofi. A short film by the DNDi tells the story of doctors in the Democratic Republic of Congo and their role in developing this revolutionary treatment. This short film has won the “Grand Prix” at the first-ever WHO “Health For All Film Festival”.
January 30, 2021 is World Neglected Tropical Diseases Day: Our congratulations to Sanofi for the inclusion of Fexinidazole Winthrop° (fexinidazole) in the “Honours List” of the 2020 Prescrire Awards!
November 5, 2020
No travel this year associated with our continuing education in medical writing due to the Covid-19 pandemic.
October 29, 2020
World Psoriasis Day was launched in 2004 and occurs every year on October 29. In recent years, Santé Active Edition – Synergy Pharm has been working with several pharmaceutical and dermo-cosmetic laboratories, and with CROs, to write and design (both in French and in English) a range of different documents on psoriasis, including a patient web file and a scientific press release, as well as several publications for peer-reviewed journals: three original articles, a review, and a supplement.
We have also reformatted the French guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults and translated them into English.
September 10, 2020
The skin microbiome, which refers to the skin microbiota and its environment, is associated with cutaneous health and disease. Learn more about the skin microbiome with the dedicated issue of “The American Journal of Clinical Dermatology”, the content of which has been written by our medical writing agency.
We thank the Laboratoires Avène who trusted us to report the 2019 edition of the “Entretiens d’Avène” in America and Asia. These conferences are always a great opportunity to update our knowledge by bringing together experts in the field from all over the world.
Synergy Pharm USA can support you from A to Z with the publication of your peer-reviewed journal supplement. We can produce your supplement from conference presentations or your study results. At our health communication agency, several scientific or medical articles can be written in parallel by our medical writers, which allows the rapid publication of the supplement after the event. Our editorial assistance and medical writing team can help to coordinate your project, reducing the delays associated with author proofreading, article review, submission and publication.
Do not hesitate to contact us to discuss your needs, we are looking forward to assisting you with your projects!